Biogen Inc
Research Biogen Inc (BIIB) on Bullrun: valuation model: 22.8% overvalued, market cap USD 32.61B, P/E 39.1. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBIIB
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Valuation signal22.8% overvalued
- Market capUSD 32.61B
- P/E39.1
- Financial periodQ2 2026
- RevenueUSD 2.74B
- Net incomeUSD 97.50M
- Free cash flowUSD 308.00M
- Gross margin71.6%
Valuation Snapshot
Bullrun's latest valuation model marks Biogen Inc as 22.8% overvalued; latest market cap is USD 32.61B; P/E is 39.1.
Peer valuation comparison
Latest P/E is 39.1x versus a Healthcare sector median of 24.46x (59.8% above).
Latest P/E is 39.1x versus a United States median of 24.87x (57.2% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 9.89B | USD 1.29B | USD 2.05B | 75.7% | 8.79 | USD 3.01B | USD 6.29B | USD 18.26B |
| FY2024 | USD 9.68B | USD 1.63B | USD 2.72B | 76.1% | 11.18 | USD 2.38B | USD 6.30B | USD 16.72B |
| FY2023 | USD 9.84B | USD 1.16B | USD 1.27B | 74.2% | 7.97 | USD 1.05B | USD 6.94B | USD 14.80B |
| FY2022 | USD 10.17B | USD 3.05B | USD 1.14B | 77.6% | 20.87 | USD 3.42B | USD 6.28B | USD 13.40B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 32.61B | 39.1 | n/a | n/a |
| 2025 | 2025-12-31 | USD 25.84B | 20.0 | n/a | n/a |
| 2024 | 2024-12-31 | USD 22.28B | 13.7 | n/a | n/a |
| 2023 | 2023-12-29 | USD 37.50B | 25.7 | n/a | n/a |
| 2022 | 2022-12-30 | USD 39.88B | 14.1 | n/a | n/a |
| 2021 | 2021-12-31 | USD 35.27B | 23.1 | n/a | n/a |
About Biogen Inc
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA;
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Biogen Inc overvalued or undervalued?
Bullrun's valuation model currently marks Biogen Inc as 22.8% overvalued.
What is Biogen Inc's market cap?
Biogen Inc's market capitalization is USD 32.61B.
What is Biogen Inc's P/E ratio?
Biogen Inc's price-to-earnings (P/E) ratio is 39.1.
What does Biogen Inc do?
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE.